HypertHyroidism can interfere with glucose metabolism through various mechanisms, and 50% of patients with thyrotoxicosis are reported to have abnormal glucose tolerance [1]. Known factors responsible for abnormal glucose tolerance include enhanced glucose absorption via the digestive tract [2, 3] and increased endogenous gluconeogenesis [4]. However, as a compensatory mechanism, excessive insulin secretion [5, 6] is typically effective; hyperglycemia is often absent even in patients with thyrotoxicosis.
ability patterns that were otherwise not possible with the self-monitoring of blood glucose (SMBG). To our knowledge, however, no studies have assessed glucose variability by CGM before and after treatment of hyperthyroidism. Here, we report a patient with Graves' disease complicated by diabetes mellitus, who presented with disturbance of endogenous insulin secretion. In this patient, hyperthyroidism resulted in not only postprandial hyperglycemia but also elevation of fasting plasma glucose (FPG) level due to the dawn phenomenon, and CGM was employed to confirm alleviation of the dawn phenomenon following improvement of thyroid function.
research design and methods
The CGM device used to assess intraday glucose variability in the presence of hyperthyroidism (CGMS system symptoms, and heart failure symptoms of the Japan Thyroid Association diagnostic criteria of thyroid storm [9] . Therefore, the diagnosis was confirmed to be thyrotoxic crisis (a score of 60 according to the diagnostic criteria of Burch et al. [10] for thyrotoxic crisis). Laboratory tests showed marked hyperglycemia, with FPG level of 212 mg/dL and hemoglobin A1c concentration of 11.2%. She was thereafter started on intensive insulin therapy, as well as treatment for acute heart failure, and also treated with propylthiouracil (300 mg/day), potassium iodide (KI; 50 mg/day), and prednisolone (PSL; 30 mg/day). The general condition improved following the treatment, and she was referred to our hospital after discontinuation of PSL and KI for further management.
On admission, she was 162.0 cm tall and weighed 44.7 kg (body mass index, 16.7 kg/m 2 ); blood pressure was 133/78 mmHg, heart rate was 80 bpm, and consciousness was clear. Diffuse goiter was noted but no exophthalmos, ocular retraction, or lid lag were evident on clinical examination. The respiratory and heart sounds were normal, and neurological examination was normal.
Laboratory tests on admission (Table 1) showed normal hepatic and renal functions, as well as normal serum electrolytes. Glucose metabolism-related tests showed reduced endogenous insulin secretion [FPG, 122 mg/dL; blood C-peptide reactivity (CPR), 0.8 ng/ mL; urinary CPR, 1.8 μg/day] associated with intensive insulin therapy. Although the disease duration was considered long based on the presence of preproliferative diabetic retinopathy, the patient had no history of ketosis. However, the family history was positive for diabetes and the patient was anti-GAD antibody-negative. Thus, the patient was diagnosed with type 2 diabetes mellitus.
On the day of admission to our hospital (hospital day 1), thyroid function tests showed free T3 level of 4.0 pg/mL and free T4 level of 2.6 ng/dL. Based on these findings, propylthiouracil treatment (300 mg/day) was continued ( Fig. 1) . With regard to treatment of diabetes mellitus, intensive insulin therapy with insulin aspart (9 U in the morning, 7 U at noon, 6 U in the evening) and insulin glargine (6 U in the evening) was continued without modification. However, glycemic control gradually worsened following the recurrence of signs of thyrotoxicosis (e.g., tachycardia, palpitation, and tremor). On hospital day 6, the FPG level was 173 mg/dL. From the fifth hospital day onward, CGM was tinuously measure glucose level in the interstitial fluid in the range of 40-400 mg/dL. The sensor is inserted into the subcutaneous tissue, and glucose levels in the interstitial fluid are converted to electrical signals, enabling measurement at 5-min intervals (288 measurement sessions per day at maximum). It has been reported that the interstitial glucose level measured by CGM correlates well with the venous blood glucose level [7] . In this study, although the CGM measured the interstitial glucose level, it was corrected by data from SMBG; thus, the interstitial glucose level is hereinafter referred to as "blood glucose level. For the values measured by CGM devices, previous data indicate ~15 to 20 mg/dL measurement error due to ~5-15 minute time lag, compared with blood glucose level measured in venous blood, in addition to a lower accuracy of measurement in hypoglycemia [8] .
During hospitalization, the patient received a diabetic diet with a daily calorie intake of 1400 kcal (25 kcal/ kg ideal body weight; 60% carbohydrate, 20-25% lipid, 15-20% protein), which was continued, without any modification, following admission to another hospital.
Case report

Clinical summary
The patient was a 48-year-old woman who was diagnosed in 1999 with Graves' disease and treated with thiamazole. She discontinued the treatment at her own discretion 6 months later following alleviation of symptoms. Around 2009, she began to lose weight and eat greater amounts of food and snacks than before. Around August 2010, she developed marked thirst, polydipsia, and polyuria. Early in January 2011, she began to experience palpitations at rest, accompanied by edema and dyspnea on effort. The dyspnea gradually worsened. Later, she developed dyspnea at rest and was transferred to a local hospital by ambulance, where physical examination showed wheezing, pitting edema of the upper and lower extremities, tachycardia, and hypoxemia, together with pulmonary congestion on radiography. She was diagnosed with congestive heart failure (New York Heart Association class 4). Signs of hyperthyroidism were noted (TSH level <0.001 μIU/mL, 2.18 ng/dL free T4), accompanied by New York Heart Association class 4 heart failure and reduced consciousness (somnolence or Glasgow Coma Scale score 12 and Japan Coma Scale score II-10), meeting the essential items, central nervous Serum thyroid hormones increased after discontinuation of potassium iodide, and hyperthyroidism was successfully treated after re-instatement of potassium iodide therapy. Daily profile of blood glucose was examined before and after resumption of potassium iodide therapy. fT3, free T3; fT4, free T4; CGM, continuous glucose monitoring; SMBG, self monitoring blood glucose. U at noon, 6 U in the evening) and insulin glargine (6 U in the evening). The dawn phenomenon, observed at approximately 0400 h during the previous CGM session, disappeared, together with marked improvement in the early morning pre-breakfast blood glucose level. However, thyroid function remained abnormal, together with persistent hyperglycemia after each meal, similar to the findings after the first CGM session (Fig. 4) . The average, SD, and mean amplitude of glycemic excursions (MAGE), as assessed by the CGM, improved with improvement in thyroid function, while the mean postprandial glucose excursion (MPPGE), reflecting postprandial hyperglycemia, did not (Table 2) . After discharge from the hospital, thyroid hormone levels returned to normal and the results of the second assessment of insulin secretion capacity were FPG 110 mg/dL and CPR 0.9 ng/mL.
discussion
To date, there have been no reports on the use of CGM to evaluate intraday glucose variability in patients with hyperthyroidism. To our knowledge, this is the first report of CGM-based evaluation of intraday glucose variability before and after management of hypercarried out to assess glucose variability. Such monitoring showed marked dawn phenomenon occurring at approximately 0400 h with postprandial hyperglycemia (Fig. 2) . From the seventh hospital day onward, the insulin dose was increased (insulin aspart: 11 U in the morning, 7 U at noon, 6 U in the evening; insulin glargine: 8 U in the evening).
Repeat thyroid function tests on hospital day 9 demonstrated deterioration of thyroid function (free T3: 11.5 pg/mL, free T4: 6.5 ng/dL, Fig. 1 ). KI (100 mg/day) was resumed the same evening. The insulin glargine dosing method and dosage were modified the following day (hospital day 10). Early morning blood glucose level began to improve before the insulin glargine dosing method and dosage was modified (Fig. 3) . The blood glucose level continued to improve rapidly after such modification. Thus, the total insulin glargine dosage was later reduced from 9 U to 6 U. The improvement also included alleviation of symptoms of thyrotoxicosis, together with falls in free T3 to 5.3 pg/mL and free T4 to 2.9 ng/dL on hospital day 16 (Fig. 1) .
After the tendency for improvement of thyroid function was confirmed, CGM was resumed to assess glucose variability on hospital day 18 under continued treatment with insulin aspart (11 U in the morning, 7 Fig. 2 Continuous glucose monitoring preformed after withdrawal of potassium iodide 1/30-31: Aspart initiated with 9 U at breakfast, 7 U at lunch and 6 U at dinner. Glargine initiated with 6 U at dinner. 2/1: Aspart initiated with 11 U at breakfast, 7 U at lunch and 6 U at dinner. Glargine initiated with 8 U at dinner.
Fig. 3
Self monitoring blood glucose preformed after the start of potassium iodide therapy 2/2: Aspart initiated with 11 U at breakfast, 7 U at lunch and 6 U at dinner. Glargine initiated with 8 U at dinner. 2/3-4: Aspart initiated with 11 U at breakfast, 7 U at lunch and 6 U at dinner. Glargine initiated with 3 U at morning and 6 U at dinner.
Fig. 4
Continuous glucose monitoring preformed after treatment with potassium iodide 2/12-14: Aspart initiated with 11 U at breakfast, 7 U at lunch and 6 U at dinner. Glargine initiated with 6 U at breakfast.
When our patient underwent the first session of CGM in the presence of thyroid hormone excess, she was found to have not only marked postprandial hyperglycemia but also early morning fasting hyperglycemia due to the marked dawn phenomenon beginning at approximately 0400 h. The dawn phenomenon is a concept proposed in 1981 by Schmidt et al. [17] . It is defined as "elevation of blood glucose level or increase in insulin demand seen towards early morning" attributed to a rise in insulin-antagonizing hormone level, increased insulin resistance in peripheral tissue, and increased gluconeogenesis [18] [19] [20] . Among insulin counter-regulatory hormones, GH secretion was especially reported to be closely related to the dawn phenomenon [21, 22] . It has been reported that excessive insulin secretion can also occur in patients with thyrotoxicosis in response to increased gluconeogenesis or insulin-antagonizing hormones through the abovementioned mechanism if glucose tolerance is normal [5, 6] . Therefore, elevation of FPG is absent in many cases. However, the dawn phenomenon was marked in the present case, probably because the compensatory mechanism mediated by insulin secretion for the management of increased gluconeogenesis and insulinantagonizing hormones had collapsed due to concomitant diabetes mellitus associated with compromised insulin secretion. In blood tests performed during the hyperthyroid state (day 9), no suppression of GH secretion was detected despite hyperglycemia; fasting blood glucose was 148 mg/dL and GH was 6.42 ng/mL. In the hyperthyroid state, 24-hour GH secretion levels are reportedly increased [23] and the suppressive effect of thyroidism. The CGM data obtained from our patient indicate that in patients with compromised basal insulin secretion, hyperthyroidism can cause not only postprandial hyperglycemia but also elevation of FPG level due to the dawn phenomenon, and in such patients, the FPG elevation associated with the dawn phenomenon, can be alleviated rapidly following improvement of thyroid function.
It has been reported that abnormal glucose tolerance is seen in 44-65% of patients with hyperthyroidism [1]. It has long been known that enhancement of gastrointestinal motility causes elevation of blood glucose levels due to increased glucose absorption via the digestive tract, the so-called oxyhyperglycemia-type postprandial hyperglycemia [2, 3] . Other mechanisms of the abnormal glucose tolerance include increased endogenous gluconeogenesis (due to thyroid hormone excess) and insulin resistance. Stimulation of the glycolysis system in the presence of thyroid hormone excess can lead to excess lactic acid, a precursor to gluconeogenesis, which enters the Cori cycle to stimulate gluconeogenesis [4] . Furthermore, thyroid hormones increase the cell membrane level of GLUT2, a major glucose transporter isoform expressed in hepatocytes [11, 12] , resulting in increased release of glucose into the blood from the liver, which serves as a cause of abnormal glucose metabolism. In the presence of thyrotoxicosis, catecholamine stimulation leads to enhanced lipid degradation, thereby increasing free fatty acids, which in turn stimulates gluconeogenesis in the liver [13, 14] . Insulin resistance also increases following the increase in free fatty acids [15] and interleukin-18 [16] . the effects of thyroid hormones on different organs and their threshold values are considered to be different. In this patient, thyroid function improved immediately (e.g., free T3 decreased from 11.54 to 5.32 pg/ mL and free T4 from 6.55 to 2.97 ng/dL) after re-administration of potassium iodide, although the function did not return to normal levels and the patient was still in a state of mild hyperthyroid state at that point. Oxyhyperglycemia associated with enhanced glucose absorption in the gut due to increased gastrointestinal motility is attributable to the actions of the small intestine alone. In contrast, the dawn phenomenon involves various organs involved in the regulation of insulin counter-regulatory hormones, peripheral insulin resistance and increased glyconeogenesis. Thus, we consider the threshold values for thyroid hormones causing oxyhyperglycemia or dawn phenomenon to be different; hence, the mild hyperthyroid state was associated with amelioration of the dawn phenomenon, though oxyhyperglycemia state remained unresolved.
CGM, performed in our patient with Graves' disease and diabetes mellitus, with compromised endogenous insulin secretion, uncovered the dawn phenomenon-associated fasting hyperglycemia associated with hyperthyroidism, and confirmed improvement of the dawn phenomenon following improvement of thyroid function. When patients with hyperthyroidism complicated by diabetes mellitus are treated, the dawn phenomenon can induce a rise in FPG level, leading to marked hyperglycemia, as seen in the present case, but glycemic control can also be restored rapidly following establishment of euthyroidism. These findings should be kept in mind when determining the strategy for treatment of diabetes mellitus in such cases.
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GH on hyperglycemia becomes inadequate [24] . Thus, in our patient, we consider the increased GH secretion level to be related to the increased thyroid function and probably contributed to the occurrence of the dawn phenomenon.
In practice, this case exhibited rapid improvement of glycemic control, as assessed by SMBG data, in response to treatment with KI. When the intraday glucose variability following improvement of thyroid function were assessed in the second CGM session, fasting hyperglycemia due to the dawn phenomenon had clearly been alleviated, compared to that observed in the presence of thyroid hormone excess. Abnormal glucose tolerance in previously untreated patients with hyperthyroidism reportedly improves in response to anti-thyroid drug treatment [25] . To our knowledge, however, there have been no reports describing improvement of the dawn phenomenon. Catecholamines are known to stimulate fat degradation during hyperthyroidism, causing increased free fatty acids during fasting in particular, thus contributing to insulin resistance [15] and gluconeogenesis in the liver [13, 14] . This may be one of the factors responsible for the dawn phenomenon observed in the present case. Other studies also reported that improvement of thyroid function can suppress catecholamine-induced fat degradation [13, 26] , suggesting that in the present case, thyroid function improvement also suppressed fat degradation and alleviated gluconeogenesis suppression and insulin resistance, leading to improvement of the dawn phenomenon.
In this patient, amelioration of the dawn phenomenon was noted as thyroid function improved, and the mean ± SD value of blood glucose and MAGE also improved, while MPPGE did not. The effects of hyperthyroidism on glycometabolism are influenced by a variety of mechanisms (e.g., those that govern the functions of the alimentary tract, circulatory dynamics, insulin secretion and insulin counter-regulatory hormones), while 
